VYNE Therapeutics, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on the stock and has a $6.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rami Katkhuda’s rating is based on the recent developments and promising data surrounding VYNE Therapeutics’ VYN202. The FDA’s decision to lift the clinical hold on the 0.25 and 0.5mg doses for female patients in the Phase Ib psoriasis trial is a significant milestone, as it addresses previous concerns about testicular toxicity observed in animal studies. This regulatory progress, coupled with the establishment of a No-Observed-Adverse-Effect Level for all clinical doses in females, strengthens the safety profile of VYN202.
Furthermore, the unblinded clinical data from the Phase Ib study, despite a small sample size, demonstrate encouraging proof-of-concept results. The reductions in serum cytokines, which are involved in the pathogenesis of psoriasis, highlight the potential of VYN202 as a treatment for autoimmune conditions. Additionally, the company’s strategic decision to not enroll more patients in the Phase Ib study extends its cash runway into Q4 2026, providing financial stability as they await further data from ongoing studies. These factors collectively contribute to the Buy rating for VYNE Therapeutics.
According to TipRanks, Katkhuda is a 4-star analyst with an average return of 15.8% and a 42.37% success rate. Katkhuda covers the Healthcare sector, focusing on stocks such as Dianthus Therapeutics, Vera Therapeutics, and VYNE Therapeutics.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $4.50 price target.